BIOMAT Database Logo BIOMAT Database Logo

c-myc amplifications in primary breast carcinomas and their local recurrences. 2006

S Aulmann, and N Adler, and J Rom, and B Helmchen, and P Schirmacher, and H P Sinn
Department of Pathology, University of Heidelberg, Heidelberg, Germany. sebastian_aulmann@med.uni-heidelberg.de

OBJECTIVE To evaluate the role of c-myc oncogene amplifications in the progression of invasive breast carcinomas. METHODS c-myc gene copy number was evaluated in a series of 49 primary breast carcinomas and the corresponding local recurrences using fluorescence in situ hybridisation. RESULTS 11 of the primary carcinomas (22%) harboured c-myc amplifications; these tumours typically were hormone receptor negative and occurred in younger patients (43 v 53 years). At the time of relapse, six additional tumours had acquired a c-myc amplification. The mean recurrence-free survival was 24 months; c-myc amplified tumours relapsed significantly earlier than carcinomas without amplification (18 v 27 months). Univariate analysis showed a worse overall survival in these patients. CONCLUSIONS While c-myc amplifications can be observed in early stage breast cancer, especially in younger patients, they often occur later in tumour development and appear to be associated with disease progression.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D011980 Receptors, Progesterone Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives. Progesterone Receptors,Progestin Receptor,Progestin Receptors,Receptor, Progesterone,Receptors, Progestin,Progesterone Receptor,Receptor, Progestin
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D005784 Gene Amplification A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication. Amplification, Gene
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

S Aulmann, and N Adler, and J Rom, and B Helmchen, and P Schirmacher, and H P Sinn
Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas.
July 1986, Proceedings of the National Academy of Sciences of the United States of America,
S Aulmann, and N Adler, and J Rom, and B Helmchen, and P Schirmacher, and H P Sinn
Evaluation of c-myc proto-oncogene in primary human breast carcinomas.
January 1991, Anticancer research,
S Aulmann, and N Adler, and J Rom, and B Helmchen, and P Schirmacher, and H P Sinn
Tumour angiogenesis and C-myc expression in breast carcinomas.
July 2004, Indian journal of pathology & microbiology,
S Aulmann, and N Adler, and J Rom, and B Helmchen, and P Schirmacher, and H P Sinn
Analysis of c-fos, c-jun, c-erbB1, c-erbB2 and c-myc in primary lung carcinomas and their lymph node metastases.
July 1994, Clinical & experimental metastasis,
S Aulmann, and N Adler, and J Rom, and B Helmchen, and P Schirmacher, and H P Sinn
[A study of amplifications of myc gene (c-myc and N-myc) in human ovarian cancer].
March 1990, Nihon Sanka Fujinka Gakkai zasshi,
S Aulmann, and N Adler, and J Rom, and B Helmchen, and P Schirmacher, and H P Sinn
Analysis of C-myc messenger-RNA expression in primary breast carcinomas with clinical follow-up.
March 1995, International journal of oncology,
S Aulmann, and N Adler, and J Rom, and B Helmchen, and P Schirmacher, and H P Sinn
An immunohistochemical and in situ hybridization study of c-myc and c-erbB-2 expression in primary human breast carcinomas.
June 1989, The Journal of pathology,
S Aulmann, and N Adler, and J Rom, and B Helmchen, and P Schirmacher, and H P Sinn
Comparison of mutation profile between primary phyllodes tumors of the breast and their paired local recurrences.
January 2020, Polish journal of pathology : official journal of the Polish Society of Pathologists,
S Aulmann, and N Adler, and J Rom, and B Helmchen, and P Schirmacher, and H P Sinn
Expression of metalloproteases and their inhibitors in primary tumors and in local recurrences after mastectomy for breast cancer.
July 2010, Journal of cancer research and clinical oncology,
S Aulmann, and N Adler, and J Rom, and B Helmchen, and P Schirmacher, and H P Sinn
Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
December 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc,
Copied contents to your clipboard!